Directorate Change

RNS Number:2947I
Profile Therapeutics PLC
05 March 2003


For Immediate Release:                                     07:10, 5 March 2003



                            Profile Therapeutics plc
                                                           
                                 Board Changes


Profile Therapeutics plc ("Profile"), which develops and commercialises
specialist inhaled therapies to improve the treatment of respiratory patients,
today announces the following Board changes.

John Ward (42), currently CFO and Company Secretary, is appointed to the Board.
John joined Profile in 1999, working as Finance Director, at subsidiary level,
and Company Secretary. John has played a key role in the financial matters of
the Group over the last four years, as well as being a hands-on member of the
Executive Team. Prior to joining Profile, John was Finance Director of Rapid
Deployment Group Limited, the UK holding company for healthcare operations of
Ventiv Health, Inc. and, before that, he was a director of corporate finance at
Price Waterhouse. He is a Chartered Accountant, having qualified as ACA in 1986
and FCA 1996. There are no matters requiring disclosure under paragraph 6.F.2
(b) to (g) of The Listing Rules in respect of John Ward.

Also announced today, is the departure of Simon Shaw, Chief Operating Officer.
As might be expected for a Company of Profile's size, to have an Executive
Chairman, a Chief Executive and a Chief Operating Officer leads to duplication
of roles and responsibilities. It has therefore been agreed that Simon will
resign as a director of the Company on 31 March 2003 and leave the business at
the end of April. Simon joined Profile in 1997 in the role of Finance Director,
before being promoted to Chief Operating Officer in 1998. He was instrumental in
the Group's successful flotation on the Full List of the London Stock Exchange
in 2000. Since then he has made substantial contributions to strategy
development and leadership of the collaborative deals that Profile has
concluded, as well as representing the Group in the investment community. The
Board of Profile would like to thank him for the significant value that he has
added to Profile and wishes him every future success.

It has also been agreed that Dr David Bloxham, Non-Executive Director, having
completed his two-year term of appointment, will retire from the Board with
effect from 4 May 2003. David joined Profile in 2001 and his advice and
experience have been instrumental in getting Profile to its current stage of
development.


                                     -ENDS-



For further information, please call:

Profile Therapeutics
Mark Kirby                                                Tel:  [phone]
John Lisle                                                Tel:  [phone]

Buchanan Communications
Nicola How / Louise Bolton                                Tel:  [phone]



Notes to Editors:

Profile Therapeutics plc develops and commercialises specialist inhaled
therapies to improve the treatment of respiratory patients.

Its first drug PromixinTM, an inhaled antibiotic for the treatment of cystic
fibrosis was launched in the UK on 3 March 2003.

Profile's portfolio of products includes the broad range of mainstay therapies
for the diseases suffered by the company's core patient groups. These are the
young, the elderly and individuals with severe respiratory impairment. The
diseases targeted by Profile include: Cystic Fibrosis, severe asthma, emphysema,
chronic bronchitis and other conditions classified as Chronic Obstructive
Pulmonary Disease ("COPD").

These patients typically use nebulisers to deliver their drugs as they are not
best served by the mass market Metered Dose Inhalers (MDI's) and Dry Powder
Inhalers (DPI's). Profile has developed proprietary innovative delivery systems
using its "intelligent inhaler" technology known as Adaptive Aerosol Delivery
technology or AAD. These systems automatically respond to individual patients'
breathing patterns to deliver a precise dose and have been shown under long term
clinical trials to significantly enhance patient compliance to therapy.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAUUUWWWUPWGMC